Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Keytruda’s Sakigake Designation Revoked after Opdivo Gastric Cancer Nod
September 29, 2017
- MHLW OKs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med, Ibrance and More
September 28, 2017
- As Complaints of Shortages Grow for Japanese Encephalitis Vaccine, MHLW Plans Centralized Collection/Feedback of Supply-Demand Data for Distributers
September 27, 2017
- Trazenta, Amoxicillin and Others under PMDA Risk Review
September 26, 2017
- Interdepartmental Cooperation Needed to Treat Symptoms Following HPV Vaccination: MHLW Panels
September 26, 2017
- MHLW to Urge Drug Makers to Create Systems to Prevent Improper Promotional Activities: Official
September 25, 2017
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters
September 22, 2017
- Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
September 21, 2017
- MHLW to Consider Use of New Comprehensive Test System to Promote Practical Use of Genomic Medicine for Cancer: Official
September 21, 2017
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines
September 20, 2017
- Japan Drug Spending Logs 1st Fall in FY2016
September 19, 2017
- MHLW Begins Discussions towards Submission of Bill to Amend Pharma Law in 2019: Official
September 19, 2017
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
- Chuikyo Working to Craft ICER Yardstick for Pilot CEA Scheme; Shiroiwa Study Leading Candidate among WTP Cost Surveys?
September 14, 2017
- Chuikyo Ponders How to Deal with ICER for Products with Multiple Indications
September 14, 2017
- Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
September 14, 2017
- JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
September 14, 2017
- With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
September 14, 2017
- JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
September 14, 2017
- (Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…